EcoDrugPlus

Dna Topoisomerase Ii Beta

Ensembl ID : ENSLCAG00010024639
Gene Symbol: TOP2B
1 Cross references
207 Possible Orthologues:

Dna Topoisomerase Ia

Ensembl ID : ENSLCAG00010019460
Gene Symbol: TOP1A
1 Cross references
207 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSLCAG00010015412
Gene Symbol: EML4
4 Cross references
207 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSLCAG00010023076
Gene Symbol: EPHA3
1 Cross references
210 Possible Orthologues:

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSLCAG00010000299
Gene Symbol: F2RL3
2 Cross references
195 Possible Orthologues:

Fau Ubiquitin Like And Ribosomal Protein S30 Fusion

Ensembl ID : ENSLCAG00010024701
Gene Symbol: FAU
2 Cross references
279 Possible Orthologues:

Fau Ubiquitin-Like And Ribosomal Protein S30

Ensembl ID : ENSLCAG00010022777
Gene Symbol: LOC108888746
4 Cross references
280 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase A

Ensembl ID : ENSLCAG00010016802
Gene Symbol: FYNA
4 Cross references
191 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase B

Ensembl ID : ENSLCAG00010002005
Gene Symbol: FYNB
4 Cross references
196 Possible Orthologues:

G Protein-Coupled Receptor 119

Ensembl ID : ENSLCAG00010023984
Gene Symbol: GPR119
4 Cross references
174 Possible Orthologues:

G-Box-Binding Factor

Ensembl ID : ENSLCAG00010027968
Gene Symbol: SI:CH211-79M20.1
3 Cross references
190 Possible Orthologues:

Hck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSLCAG00010001041
Gene Symbol: HCK
4 Cross references
202 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).